Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes

Abstract The role of the compromised immune microenvironment, including immune checkpoints, in myelodysplastic syndromes (MDS) has been identified as critical This study aimed to investigate the expression patterns of immune checkpoints, particularly soluble PD-1/PD-L1 (sPD-1/sPD-L1) as well as PD-1...

Full description

Bibliographic Details

Published in:	Biomarker Research
Main Authors:	Xingcheng Yang, Lijun Jiang, Xiaoying Zhang, Juan Peng, Hu Qian, Lifang Huang, Shaolong He, Zhiqiong Wang, Liting Chen, Yicheng Zhang, Ling Ma, Yuan Chen, Jia Wei
Format:	Article
Language:	English
Published:	BMC 2024-10-01
Subjects:	Myelodysplastic syndromes PD-1/PD-L1 signaling pathway Soluble immune checkpoints Cytokines Hypomethylating agents
Online Access:	https://doi.org/10.1186/s40364-024-00665-y